N (%) | Mean | SD | Range | |
---|---|---|---|---|
Mean age, years | 65.2 | 8.6 | 43–80 | |
Gender | ||||
Male | 40 (69.0) | |||
Female | 18 (31.0) | |||
Chemotherapy | ||||
XELOX | 18 (31.0) | |||
XELOX + BV | 40 (69.0) | |||
ECOG PS | ||||
0 | 47 (81.0) | |||
1 | 11 (19.0) | |||
2 | 0 (0) | |||
3 | 0 (0) | |||
Primary cancer | ||||
Colon | 31 (53.4) | |||
Rectum | 27 (46.6) | |||
Adverse events (Grade 3–4) | ||||
Hematological | 7 (12.1) | |||
Non-hematological | 10 (17.2) | |||
Oxaliplatin (mg/body) | 1751 | 136.6 | 345–5903 |